INDICAL acquires Salmonella and antimicrobial resistance diagnostics company


Today INDICAL is taking the first step into food safety and antimicrobial resistance segments by joining forces with Check-Points.

Check-Points is a Dutch R&D focused company that produces tests for two principal markets – food safety and human antimicrobial resistance. The main component of the business is related to “Check and Trace”, a unique product based on a microarray platform to accurately identify over 300 serotypes of Salmonella. The company, founded in 2002 with annual revenues of approximately EUR 2.3 million, also produces a number of DNA-based tests for the molecular detection of antimicrobial resistance in hospital acquired infections in humans.

Through the Salmonella test, the company principally serves producers and labs within the poultry industry as well as food safety labs. The human assays principally target in-hospital laboratories.

“The acquisition of Check-Points bolsters our poultry portfolio and direct-to-producer offering. Check-Points has developed strong momentum in its core products and has an exciting R&D pipeline, with highly relevant development expertise that can support new projects within INDICAL itself. We look forward to working with the Check-Points management team to take advantage of all these opportunities”, says Stefano Santarelli, CEO of INDICAL BIOSCIENCE.

Antimicrobial resistance (AMR) is a global health and development threat that requires urgent action in order to achieve the Sustainable Development Goals (SDGs) and is declared as one of the top 10 global public health threats facing humanity by the World Health Organization (WHO). Having Check-Points as part of the family is a great step towards INDICAL’s contribution to One Health – of the planet, animals and people.

Read the full press release here